Novo Nordisk Dirección

Dirección controles de criterios 3/4

El CEO de Novo Nordisk es Lars Jorgensen, nombrado en Jan 2017, tiene una permanencia de 7.83 años. posee directamente un 0.002% de las acciones de la empresa, con un valor de $9.23M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 6.7 años, respectivamente.

Información clave

Lars Jorgensen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.8yrs
Participación del CEO	0.002%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lars Jorgensen en comparación con los beneficios de Novo Nordisk?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	DKK 95b
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Lars es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: La compensación de Lars ha sido consistente con los resultados de la empresa en el último año.

CEO

Lars Jorgensen (58 yo)

7.8yrs

Permanencia

DKK 60,100,000

Compensación

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Jorgensen	President	7.8yrs	DKK 60.10m	0.0021% $ 9.3m
Karsten Knudsen	Executive VP	6.8yrs	DKK 21.50m	0.000010% $ 44.5k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% $ 266.8k
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	sin datos
Martin Lange	Executive VP of Development & Member of the Management Board	3.8yrs	DKK 20.90m	sin datos
Marcus Schindler	EVP of Research & Early Development	3.7yrs	DKK 20.90m	sin datos
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	sin datos	0.0011% $ 5.0m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	sin datos	sin datos
Ludovic Helfgott	Executive VP	no data	sin datos	sin datos
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.7yrs	sin datos	sin datos
David Moore	Executive VP of Corporate Development & Member of Management Board	1.7yrs	sin datos	sin datos
Jacob Martin Rode	Head of Investor Relations	no data	sin datos	sin datos

3.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NONO.F se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sylvie Gregoire	Independent Director	9.7yrs	DKK 1.80m	sin datos
Helge Lund	Independent Chairman of the Board	7.7yrs	DKK 3.10m	sin datos
Henrik Poulsen	Vice Chairman of the Board	3.7yrs	DKK 2.00m	sin datos
Laurence Debroux	Independent Director	5.7yrs	DKK 2.00m	sin datos
Martin MacKay	Independent Director	6.7yrs	DKK 1.70m	sin datos
Andreas Fibig	Independent Director	6.7yrs	DKK 1.40m	sin datos
Kasim Kutay	Non-Independent Director	7.7yrs	DKK 1.20m	sin datos
Christina Law	Independent Director	2.7yrs	DKK 1.30m	sin datos
Liselotte Hyveled	Employee Representative Director	2.7yrs	DKK 800.00k	0% $ 0
Mette Jensen	Employee Non-Independent Representative Director	6.7yrs	DKK 1.20m	sin datos
Thomas Rantzau	Employee Representative Non-Independent Director	6.8yrs	DKK 1.00m	sin datos
Elisabeth Christensen	Employee Representative Director	2.7yrs	DKK 800.00k	sin datos

6.7yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NONO.F se considera experimentada (6.7 años de antigüedad promedio).

Novo Nordisk Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025

Novo Nordisk A/S Provides Earnings Guidance for 2024

Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad